Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Action Research Group | OTHER |
| Hôpital Lariboisière Fernand Widal | OTHER |
Not provided
Not provided
Not provided
Not provided
New-onset of atrial fibrillation (AF) and atrial arrythmia (AA) in general, is important as it exposes patients to stroke or other embolic complications not to mention the risk of heart failure. AF detection in high risk populations such as patients with a recent stroke or TIA or, symptomatic patients with multiple risk factors for AF, is performed with long-term electrocardiography monitoring using frequently implantable loop recorders (ILR). These recorders have their own limitations related to the invasive nature of the device implanted under the skin of the chest with limited acceptation by the patients. Smart watches appear as useful alternatives, but they need to be evaluated in an all-comer population of patients highly exposed to AF, different from the large population studies conducted in healthy young adults with a low incidence of AF. The unique features of CardiacSense Medical System suggest that we could have an accurate noninvasive detection of AF in a selected population very much exposed to the risk of atrial fibrillation, the most frequent atrial arrhythmia.
Study design :
This clinical investigation is a comparative, non-randomised, one group, controlled study.
Each patient represents its own control. The study will envolve 400 participants
Hypothesis :
Our hypothesis is that CardiacSense Medical System is an effective, safe, and better accepted alternative for detecting atrial fibrillation (AF) in a high-risk population than implantable loop recorders (ILRs).
Population :
Any patient aged 18 years or more, with an ILR implanted for the detection of AF will be eligible. The time of implantation will not matter as long as the batteries work. Each patient will be proposed a CS Medical Watch for a period corresponding to the period at risk of AF.
Main objective :
To compare the performance of the CardiacSense Medical Watch by pulse plethysmography (PPG) only to the gold standard method of ILR monitoring, to detect AF that lasts 5 minutes or more, in a population of patients at high risk of paroxysmal AF.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort group | Other | Patients will be followed during a period ranging from 3 to 12 months depending on his period at risk of AF. This period will be defined at the inclusion visit. During this period, the patient will be followed as part of usual care, considering the medical informations given by the ILR device already implanted. During this period, the patient will have to wear the watch permanently outside charging time. Moreover, he will have to realize ECG measurement when the Medical Watch will indicate it. The patient could also trigger an ECG measurement if he feels the need. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CS Medical Watch | Device | The Use of the CS Medical Watch during the participation period of the clinical investigation (between 3 and 12 months according to the period at risk of AF). |
| Measure | Description | Time Frame |
|---|---|---|
| The total number of episodes AF that lasts 5 min or more recorded on long-term monitoring | The total number of episodes AF that lasts 5 min or more recorded on long-term monitoring using the CardiacSense Medical Watch by pulse plethysmography (PPG) only vs the gold standard method of ILR ECG recording, over the same period of monitoring by the two devices for each patient. | between 3 and 12 months according to the period at risk of AF |
| Measure | Description | Time Frame |
|---|---|---|
| The total number of AA episodes that lasts 5 min or more recorded on long-term monitoring | The total number of AA episodes that lasts 5 min or more detected by PPG and confirmed by ECG measurement of the CardiacSense Medical Watch (vs. ILR ECG recording) over the same period of monitoring by the two devices for each patient. | between 3 and 12 months according to the period at risk of AF |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Gilles MONTALESCOT, Prof | Contact | 0142163007 | +33 | gilles.montalescot@aphp.fr |
| Marine CAMUS, Mrs | Contact | 0140274076 | +33 | marine.camus2@aphp.fr |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001281 | Atrial Fibrillation |
| ID | Term |
|---|---|
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
Not provided
Not provided
This clinical investigation is a comparative, one group, controlled study.
Each patient represents its own control. Patients with an ILR already implanted for the detection of AF will receive a CS Medical Watch for a period corresponding to the period at risk of AF, up to 1 year maximum.
For each patient, results obtained with the ILR device will be compared to results obtained with the CS Medical Watch device.
During the conduct of the study, all medical decisions will be taken according to the ILR already implanted. No medical decision will be taken on CardiacSense System information collected during the study.
Not provided
Not provided
Not provided
Not provided
| Specific questionnaire | Other | Specific questionnaire during the last study visit (takes place at M3 to M12 according to the period at risk of AF) |
|
| The total number of episodes AF that lasts 5 min or more recorded on long-term monitoring | Same primary endpoint for symptomatic patients vs. asymptomatic patients | between 3 and 12 months according to the period at risk of AF |
| The total duration of AF episodes that lasts 5 min or more | Total duration of AF episodes that lasts 5 min or more / total duration of monitoring expressed in % for each device (PPG CS watch only vs. ILR ECG recording). | between 3 and 12 months according to the period at risk of AF |
| Incidence and severity of CS device vs ILR devices | Related Adverse Events and incidents during the patient participation | between 3 and 12 months according to the period at risk of AF |
| Degree of invasiveness, comfort, and ease of use of both devices | Description : measured using specific questionnaires for the study | between 3 and 12 months according to the period at risk of AF |
| Medico-economic evaluation according to the AP-HP hospital costs |
| between 3 and 12 months according to the period at risk of AF |
| D013568 |
| Pathological Conditions, Signs and Symptoms |